Medscape reports the finding on nail separation, while experts quoted say more research is needed and caution doctors against alarming patients.
Recap by typeshit. Post by Medscape on X.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
In a four month trial of 39 adults, both groups regained about 3.6% of body weight versus 10.75% with usual care. Researchers say larger, longer studies are needed.
Full phase 3 data from EASD and The Lancet: 1,152 adults, three doses over 80 weeks, A1C down about 1.5 points, with diarrhea and nausea the top side effects.
Loading…